Logo image of NXTC

NEXTCURE INC (NXTC) Stock Fundamental Analysis

NASDAQ:NXTC - Nasdaq - US65343E1082 - Common Stock - Currency: USD

0.4895  -0.02 (-3.34%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NXTC. NXTC was compared to 561 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for NXTC as it has an excellent financial health rating, but there are worries on the profitability. NXTC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NXTC had negative earnings in the past year.
In the past year NXTC has reported a negative cash flow from operations.
NXTC had negative earnings in each of the past 5 years.
In the past 5 years NXTC always reported negative operating cash flow.
NXTC Yearly Net Income VS EBIT VS OCF VS FCFNXTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

The Return On Assets of NXTC (-73.76%) is worse than 67.20% of its industry peers.
The Return On Equity of NXTC (-88.66%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -73.76%
ROE -88.66%
ROIC N/A
ROA(3y)-39.39%
ROA(5y)-27.92%
ROE(3y)-43.05%
ROE(5y)-30.42%
ROIC(3y)N/A
ROIC(5y)N/A
NXTC Yearly ROA, ROE, ROICNXTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

NXTC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NXTC Yearly Profit, Operating, Gross MarginsNXTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300 -400 -500

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, NXTC has more shares outstanding
NXTC has more shares outstanding than it did 5 years ago.
There is no outstanding debt for NXTC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NXTC Yearly Shares OutstandingNXTC Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
NXTC Yearly Total Debt VS Total AssetsNXTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -9.03, we must say that NXTC is in the distress zone and has some risk of bankruptcy.
NXTC has a worse Altman-Z score (-9.03) than 72.55% of its industry peers.
NXTC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.03
ROIC/WACCN/A
WACCN/A
NXTC Yearly LT Debt VS Equity VS FCFNXTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

NXTC has a Current Ratio of 10.26. This indicates that NXTC is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 10.26, NXTC belongs to the best of the industry, outperforming 80.21% of the companies in the same industry.
NXTC has a Quick Ratio of 10.26. This indicates that NXTC is financially healthy and has no problem in meeting its short term obligations.
NXTC has a better Quick ratio (10.26) than 80.21% of its industry peers.
Industry RankSector Rank
Current Ratio 10.26
Quick Ratio 10.26
NXTC Yearly Current Assets VS Current LiabilitesNXTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

NXTC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.81%, which is quite impressive.
EPS 1Y (TTM)22.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

NXTC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.85% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y13.19%
EPS Next 2Y13.2%
EPS Next 3Y10.57%
EPS Next 5Y10.85%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NXTC Yearly Revenue VS EstimatesNXTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2028 2029 2030 10M 20M 30M 40M
NXTC Yearly EPS VS EstimatesNXTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3 -4 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NXTC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NXTC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NXTC Price Earnings VS Forward Price EarningsNXTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NXTC Per share dataNXTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.2%
EPS Next 3Y10.57%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NXTC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEXTCURE INC

NASDAQ:NXTC (5/22/2025, 2:26:35 PM)

0.4895

-0.02 (-3.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01/amc
Earnings (Next)07-30 2025-07-30/amc
Inst Owners48.29%
Inst Owner Change-4.18%
Ins Owners1.81%
Ins Owner Change0%
Market Cap13.73M
Analysts82.5
Price Target3.06 (525.13%)
Short Float %0.73%
Short Ratio1.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.79%
Min EPS beat(2)-19.99%
Max EPS beat(2)4.41%
EPS beat(4)1
Avg EPS beat(4)-18.81%
Min EPS beat(4)-43.15%
Max EPS beat(4)4.41%
EPS beat(8)3
Avg EPS beat(8)-10.21%
EPS beat(12)6
Avg EPS beat(12)-5.09%
EPS beat(16)8
Avg EPS beat(16)-3.66%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-14.29%
EPS NQ rev (1m)9.41%
EPS NQ rev (3m)-1.32%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.25
P/tB 0.25
EV/EBITDA N/A
EPS(TTM)-1.76
EYN/A
EPS(NY)-1.62
Fwd EYN/A
FCF(TTM)-1.48
FCFYN/A
OCF(TTM)-1.47
OCFYN/A
SpS0
BVpS1.99
TBVpS1.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -73.76%
ROE -88.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.39%
ROA(5y)-27.92%
ROE(3y)-43.05%
ROE(5y)-30.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.26
Quick Ratio 10.26
Altman-Z -9.03
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)43.39%
Cap/Depr(5y)92.91%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.07%
EPS Next Y13.19%
EPS Next 2Y13.2%
EPS Next 3Y10.57%
EPS Next 5Y10.85%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-24.5%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y31.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.97%
OCF growth 3YN/A
OCF growth 5YN/A